Schroeder Discusses Limits on Use of Nondisclosure Agreements in Sexual Harassment Settlements
December 4, 2017
Wired
Partner Don Schroeder is quoted in a Wired magazine article, “How to Pierce the Secrecy around Sexual Harassment Cases,” about proposed restrictions on the use of nondisclosure agreements in sexual harassment settlements.
Schroeder said employers would likely resist a requirement that they reveal prior complaints against an accused harasser when discussing a new settlement, saying parties already have the ability to ask about prior complaints if they file a lawsuit. “I’m not sure that an employer would even be inclined to settle a claim if they had to share upfront and before litigation all of that information,” he said.
Schroeder said employers would likely resist a requirement that they reveal prior complaints against an accused harasser when discussing a new settlement, saying parties already have the ability to ask about prior complaints if they file a lawsuit. “I’m not sure that an employer would even be inclined to settle a claim if they had to share upfront and before litigation all of that information,” he said.
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."